04.09.19
The Center for Process Innovation (CPI) is collaborating with partners GSK and AstraZeneca to establish a bespoke, continuous wet granulation manufacturing facility for small-scale development of oral solid dosage pharmaceuticals.
The new facility, built as part of a project called PROSPECT CP, will include blending and feeding of raw materials, twin screw wet granulation, drying and ultimately tableting. The facility is designed to include integrated in-line process analytical technologies (PAT). This suite of analytical sensors is placed at the end of the granulator to monitor important in-process product attributes in real time. Data from the in-line sensors will be used to build models, which will predict finished product attributes from the in-process measurements, enabling robust control of product quality to be achieved.
The facility will be based at CPI’s existing facilities at NETPark, Co. Durham, will be capable of handling a wide range of active pharmaceutical ingredients and will include equipment relevant to established continuous manufacturing technologies.
Once complete, the capability will be available as an in-line, PAT-enabled, open-innovation facility to support the UK pharmaceutical industry and potentially other industries where the development of controlled complex solid forms is critical. It will be ideally suited to the rapid development of robust processes enabling reduced development timelines. However, it could also be used in the future to aid real-time monitoring and control of product quality. The longer-term ambition is to reduce or remove the need for labor-intensive testing of products at the end of manufacture and decreasing drug release timeframes.
A prototype of the facility has been constructed, and work is continuing on the integration of sensors and controls with the manufacturing equipment.
“We are delighted that CPI has been able to support this massive step forward in the understanding of complex particles,” said Graeme Cruickshank, director of formulation, CPI. “Creating the infrastructure needed to develop UK-led fundamental learning in this high value area will enable us to drive innovation forward in the pharmaceutical sector, as well as many others.”
Jason Crooks, director, drug product design and development, GSK, said, “GSK is proud to be working with CPI to develop the PROSPECT CP platform. The work progressed on PROSPECT CP over the next two years will provide a much-needed springboard to accelerate incubation and translation of emerging process analytical technologies to the pharma business.”
Kevin Sutcliffe, principal scientist, global product development, AstraZeneca, said, “Creating the PAT test bed on the PROSPECT CP platform will enable industry to acquire process data using new and existing analytical technologies. Our collaboration with CPI will complement our own work in AstraZeneca on building models that show the relevance of raw material characteristics and process measurements to product quality.”
The new facility, built as part of a project called PROSPECT CP, will include blending and feeding of raw materials, twin screw wet granulation, drying and ultimately tableting. The facility is designed to include integrated in-line process analytical technologies (PAT). This suite of analytical sensors is placed at the end of the granulator to monitor important in-process product attributes in real time. Data from the in-line sensors will be used to build models, which will predict finished product attributes from the in-process measurements, enabling robust control of product quality to be achieved.
The facility will be based at CPI’s existing facilities at NETPark, Co. Durham, will be capable of handling a wide range of active pharmaceutical ingredients and will include equipment relevant to established continuous manufacturing technologies.
Once complete, the capability will be available as an in-line, PAT-enabled, open-innovation facility to support the UK pharmaceutical industry and potentially other industries where the development of controlled complex solid forms is critical. It will be ideally suited to the rapid development of robust processes enabling reduced development timelines. However, it could also be used in the future to aid real-time monitoring and control of product quality. The longer-term ambition is to reduce or remove the need for labor-intensive testing of products at the end of manufacture and decreasing drug release timeframes.
A prototype of the facility has been constructed, and work is continuing on the integration of sensors and controls with the manufacturing equipment.
“We are delighted that CPI has been able to support this massive step forward in the understanding of complex particles,” said Graeme Cruickshank, director of formulation, CPI. “Creating the infrastructure needed to develop UK-led fundamental learning in this high value area will enable us to drive innovation forward in the pharmaceutical sector, as well as many others.”
Jason Crooks, director, drug product design and development, GSK, said, “GSK is proud to be working with CPI to develop the PROSPECT CP platform. The work progressed on PROSPECT CP over the next two years will provide a much-needed springboard to accelerate incubation and translation of emerging process analytical technologies to the pharma business.”
Kevin Sutcliffe, principal scientist, global product development, AstraZeneca, said, “Creating the PAT test bed on the PROSPECT CP platform will enable industry to acquire process data using new and existing analytical technologies. Our collaboration with CPI will complement our own work in AstraZeneca on building models that show the relevance of raw material characteristics and process measurements to product quality.”
